“Growing Shift Toward Minimally Invasive and Targeted Pharmacologic Interventions”
• A prominent trend in the global pleural effusion drug market is the increasing preference for targeted pharmacologic therapies that reduce the need for repeated drainage procedures or invasive interventions.
• Treatment protocols now favor combinations of anti-inflammatory agents, antibiotics, and fibrinolytics delivered intrapleurally or systemically, minimizing complications and improving patient comfort.
• For example, fibrinolytic drugs like alteplase and dornase alfa, when used in combination, have shown improved outcomes in managing complicated parapneumonic effusions and empyema.
• Technological innovations such as catheter-directed drug delivery systems and intrapleural pumps are enhancing localized therapeutic efficacy.
• Increasing global burden of respiratory infections and malignancies is contributing to the rising demand for more effective, less invasive drug-based management of pleural effusion.
